Wellcome Centre for Human Genetics, Oxford University, Oxford, United Kingdom.
Clinical Ethics, Law and Society (CELS) Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.
Biopreserv Biobank. 2023 Jun;21(3):275-281. doi: 10.1089/bio.2021.0172. Epub 2022 Aug 16.
The past few decades have seen rapid increases in the size and scope of biobanks, with large-scale publicly funded ventures supporting health-related research becoming the norm. As these biobanks are increasingly asked to share their data, including for example, genome-wide analyses, questions arise about how such decisions are made, including whether applicants' research aligns with the aims of the biobank. To better understand how biobanks make decisions relating to their data use, we sought the views and experiences of those involved in decision-making relating to data access at 11 large-scale publicly funded health biobanks. We were particularly interested in how potentially contentious applications were approached. Interviewees had some concerns about decisions on applications they felt their governance structures could not reach. We ask broader questions about the responsibility of those involved in biobank access decisions-those working early in the research process-when considering such issues.
在过去的几十年中,生物银行的规模和范围迅速扩大,大规模的公共资助风险投资支持与健康相关的研究已成为常态。随着这些生物银行越来越多地被要求共享其数据,包括例如全基因组分析,人们开始质疑这些决策是如何做出的,包括申请人的研究是否符合生物银行的目标。为了更好地了解生物银行如何就其数据使用做出决策,我们征求了参与 11 个大型公共资助健康生物银行数据访问决策制定的人员的意见和经验。我们特别关注如何处理可能有争议的申请。受访者对他们认为自己的治理结构无法涉及的申请决策有些担忧。当考虑到这些问题时,我们询问了那些参与生物库访问决策的人的责任,这些人在研究过程的早期阶段工作。